United States · FDA National Drug Code directory
Abrysvo
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0069-2465_c3db32ba-8a3e-47d3-9dde-26a65f7bd0c0
- Product NDC
- 0069-2465
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- Respiratory Syncytial Virus Vaccine
- Labeler
- Pfizer Laboratories Div Pfizer Inc
- Marketing category
- BLA
- Marketing start / end (source format)
- 20240730
- Source listing expiry
- 20271231
Source-listed ingredients
- RECOMBINANT STABILIZED RSV A PREFUSION F ANTIGEN — .06 mg/.5mL
- RECOMBINANT STABILIZED RSV B PREFUSION F ANTIGEN — .06 mg/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL in 1 CARTON (0069-2465-01) / .5 mL in 1 VIAL (0069-2465-19) · 0069-2465-01
- 10 VIAL in 1 CARTON (0069-2465-10) / .5 mL in 1 VIAL (0069-2465-19) · 0069-2465-10
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →